BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 11784312)

  • 21. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
    Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
    J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Localization of a vitronectin binding region of plasminogen activator inhibitor-1.
    Padmanabhan J; Sane DC
    Thromb Haemost; 1995 May; 73(5):829-34. PubMed ID: 7482411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
    Stahl A; Mueller BM
    Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
    Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
    J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. uPA binding to PAI-1 induces corneal myofibroblast differentiation on vitronectin.
    Wang L; Ly CM; Ko CY; Meyers EE; Lawrence DA; Bernstein AM
    Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4765-75. PubMed ID: 22700714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2.
    Stefansson S; Lawrence DA; Argraves WS
    J Biol Chem; 1996 Apr; 271(14):8215-20. PubMed ID: 8626514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
    Lobov S; Ranson M
    Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
    Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
    Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.
    Germer M; Kanse SM; Kirkegaard T; Kjøller L; Felding-Habermann B; Goodman S; Preissner KT
    Eur J Biochem; 1998 May; 253(3):669-74. PubMed ID: 9654064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
    Bajou K; Masson V; Gerard RD; Schmitt PM; Albert V; Praus M; Lund LR; Frandsen TL; Brunner N; Dano K; Fusenig NE; Weidle U; Carmeliet G; Loskutoff D; Collen D; Carmeliet P; Foidart JM; Noël A
    J Cell Biol; 2001 Feb; 152(4):777-84. PubMed ID: 11266468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices.
    Garg N; Goyal N; Strawn TL; Wu J; Mann KM; Lawrence DA; Fay WP
    J Thromb Haemost; 2010 Aug; 8(8):1847-54. PubMed ID: 20492459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin.
    Sorrell AM; Shand JH; Tonner E; Gamberoni M; Accorsi PA; Beattie J; Allan GJ; Flint DJ
    J Biol Chem; 2006 Apr; 281(16):10883-9. PubMed ID: 16505491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intra- and extracellular plasminogen activator inhibitor-1 regulate effect of vitronectin against radiation-induced endothelial cell death.
    Hazawa M; Yasuda T; Saotome-Nakamura A; Tomiyama K; Obara C; Goto T; Tajima K
    Vascul Pharmacol; 2016 Dec; 87():150-158. PubMed ID: 27650166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
    Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
    J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Localization of vitronectin binding domain in plasminogen activator inhibitor-1.
    Lawrence DA; Berkenpas MB; Palaniappan S; Ginsburg D
    J Biol Chem; 1994 May; 269(21):15223-8. PubMed ID: 7515053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin.
    Fa M; Karolin J; Aleshkov S; Strandberg L; Johansson LB; Ny T
    Biochemistry; 1995 Oct; 34(42):13833-40. PubMed ID: 7577977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A steady-state competition model describes the modulating effects of thrombomodulin on thrombin inhibition by plasminogen activator inhibitor-1 in the absence and presence of vitronectin.
    Dekker RJ; Pannekoek H; Horrevoets AJ
    Eur J Biochem; 2003 May; 270(9):1942-51. PubMed ID: 12709053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
    Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
    Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.